Catalent Inc has announced that it has agreed to acquire Accucaps Industries Limited (Accucaps), the Canada-based developer and manufacturer of Over-the-Counter (OTC), high potency and conventional pharmaceutical softgels. Financial details of the transaction have not been disclosed.
The acquisition, which is subject to Canadian governmental approval, will substantially complement Catalent’s global OTC and prescription pharmaceutical softgel capabilities and capacity with the addition of a portfolio of products supplied to pharmaceutical companies in North America, and two facilities offering integrated softgel development, manufacturing and packaging, strengthening Catalent’s ability to offer customers turnkey solutions.
Commenting on the acquisition, Dr. Aris Gennadios, Catalent’s President of Softgel Technologies, said, “Significant investments already made by Accucaps align well with Catalent’s own strategic goals, to offer our customers access to more products, capacity, and integrated solutions for differentiated products and better treatments.”
Upon completion of the acquisition, Accucaps’ over 500 employees, at its two facilities in Windsor and Strathroy, Ontario, will join Catalent’s global network of 11 Softgel Technologies facilities. The Accucaps facilities house sizeable blistering, bottling and other packaging capabilities, as well as high-potency prescription softgel development and manufacturing expertise that are complementary to Catalent’s.
Catalent RP Scherer Softgel is a global leader in innovative oral and topical softgel technologies for the pharmaceutical, consumer health, and cosmetics markets. Its softgel technologies are proven to solve complex bioavailability and formulation challenges, and are preferred in a wide range of consumer health and pharmaceutical product categories.
Catalent leverages more than 80 years of experience in softgel formulation, development and manufacturing, as well as its proactively developed products, to help customers bring products to market faster. With a variety of unique, innovative technologies, and highly versatile, most preferred dose forms, Catalent has a wide variety of solutions to meet its customers’ needs. Catalent was advised by RBC Capital Markets.
Source: Story from Catalent Inc. Please note: The content above may have been edited to ensure it is in keeping with Technology Networks' style and length guidelines.